首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

1741115

凝血酶抑制劑市場：按類型、應用和地區分類

Thrombin Inhibitor Market, By Type, By Application, By Geography

出版日期: 2025年03月26日 | 出版商:

Coherent Market Insights | 英文 160 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

凝血酶抑制劑市場規模預計在 2025 年為 346.8 億美元，預計到 2032 年將達到 528.4 億美元，2025 年至 2032 年的年複合成長率（CAGR）為 6.2%。

報告範圍		報告詳細資訊
基準年	2024	2025年的市場規模	346.8億美元
效能數據	2020-2024	預測期	2025-2032
預測期間：2025年至2032年的複合年成長率	6.20%	2032年價值預測	528.4億美元

凝血酶抑制劑是一類抗凝血劑（或一類具有抗凝血作用的藥物），它們與凝血酶結合並抑制其活性，阻止血栓形成。它們用於預防動脈和靜脈血栓症、預防和治療深層靜脈栓塞症，以及預防心房顫動引起的血栓性栓塞症。

使用凝血酶抑制劑治療的疾病包括急性冠狀動脈症候群、心臟血栓、肝素誘發的血小板減少性疾病(HIT)、靜脈血栓栓塞症(VTE)、心房顫動 (Afib)、深層靜脈栓塞症(DVT) 和肺動脈栓塞。

目前醫療保健專業人員使用的直接凝血酶抑制劑包括阿加曲班（靜脈注射）、比伐盧定（靜脈注射）和Dabigatran（錠劑）。

市場動態

深層靜脈栓塞症(DVT)、肺動脈栓塞(PE) 和心房顫動 (AF) 的盛行率/發病率不斷上升、對安全有效治療的需求不斷增加（由於全球人民的意識不斷增強）、研發 (R&D) 不斷增加以及新型抗凝血藥物的推出是預期推動全球凝血酶抑制劑市場成長的關鍵因素。

例如，2018年6月，邁蘭公司（Mylan NV）宣佈在美國上市注射用比伐盧定（Bivalirudin for Injection），學名藥。本產品為直接凝血酶抑制劑，採用250毫克單劑量管瓶，適用於患者抗凝血。在美國食品藥物管理局（FDA）核准該產品的簡化新藥認證申請（ANDA）後，邁蘭公司將向醫院和醫療機構提供比伐盧定。

研究的主要特點

本報告對全球凝血酶抑制劑市場進行了詳細分析，並介紹了預測期（2025-2032）的市場規模和複合年成長率。
它還強調了各個領域的潛在商機，並說明了該市場的引人注目的投資提案矩陣。
它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景和主要企業採用的競爭策略的重要見解。
該報告涵蓋了全球凝血酶抑制劑市場的主要企業概況，基於以下參數，例如公司亮點、產品系列、關鍵亮點、性能和策略。
本報告的見解將使負責人和企業經營團隊能夠就未來的產品發布、新興趨勢、市場擴張和行銷策略做出明智的決策。
全球凝血酶抑制劑市場報告迎合了該行業的各個相關人員，例如投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
相關人員將透過全球凝血酶抑制劑市場分析中使用的各種策略矩陣更輕鬆地做出決策。

介紹
北美洲
- 美國
- 加拿大
歐洲
- 英國
- 德國
- 法國
- 義大利
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 東南亞國協
- 其他亞太地區
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲
中東
- 海灣合作理事會國家
- 以色列
- 其他中東地區
非洲
- 南非
- 北非
- 中部非洲

第8章競爭態勢

Eisai Co., Ltd.
Merck & Co., Inc.
Novartis International AG
GlaxoSmithKline plc
AbbVie Inc.
Portola Pharmaceuticals, Inc.
CSL Behring
Johnson & Johnson
Sanofi SA
Bayer AG
Pfizer Inc.
Bristol Myers Squibb
Boehringer Ingelheim GmbH
Daiichi Sankyo Company
Aspen Pharmacare Holdings Limited

第9章章節

調查方法
關於出版商

簡介目錄

Product Code: CMI5835

Thrombin Inhibitor Market is estimated to be valued at USD 34.68 Bn in 2025 and is expected to reach USD 52.84 Bn by 2032, growing at a compound annual growth rate (CAGR) of 6.2% from 2025 to 2032.

Report Coverage		Report Details
Base Year:	2024	Market Size in 2025:	USD 34.68 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	6.20%	2032 Value Projection:	USD 52.84 Bn

Thrombin inhibitors are anticoagulants (or are a class of medication that act as anticoagulants) that bind to and inhibit the activity of thrombin, and therefore prevent blood clot formation. They are used to prevent arterial and venous thrombosis, as well as prevent and treat deep vein thrombosis and as prophylaxis in atrial fibrillation to avoid thromboembolism.

The conditions treated with thrombin inhibitors are; Acute Coronary Syndrome, Blood clots in heart, Heparin-induced thrombocytopenia (HIT), Venous thromboembolism (VTE), Atrial Fibrillation (Afib), Deep vein thrombosis (DVT), Pulmonary Embolism.

Direct thrombin inhibitor drugs that healthcare providers currently use include; Argatroban (IV injection), Bivalirudin (IV injection), Dabigatran (pill form).

Market Dynamics:

The increasing prevalence/incidence of deep vein thrombosis (DVT), pulmonary embolism (PE), and atrial fibrillation (AF), a rise in demand for safe and effective treatment (due to increasing awareness among people worldwide), increase in research and development (R&D), and introduction of novel anticoagulants are major factors expected to propel the growth of the global thrombin inhibitor market.

For instance, in June 2018, Mylan N.V. announced the U.S. launch of Bivalirudin for Injection, a generic version of Angiomax. The product, 250 mg single-dose vial, is a direct thrombin inhibitor indicated for use as an anticoagulant in patients. Mylan is offering Bivalirudin to its hospital and institutional customers after an Abbreviated New Drug Application (ANDA) for the product was approved by the U.S. Food and Drug Administration (FDA).

Key features of the study:

This report provides an in-depth analysis of the global thrombin inhibitor market, and provides market size (US$ Billion) and compound annual growth rate (CAGR %) for the forecast period (2025-2032)
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global thrombin inhibitor market based on the following parameters such as company highlights, product portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Eisai Co., Ltd., Merck & Co., Inc., Novartis International AG, GlaxoSmithKline plc, AbbVie Inc., Portola Pharmaceuticals, Inc., CSL Behring, Johnson & Johnson, Sanofi S.A., Bayer AG, Pfizer Inc., Bristol Myers Squibb, Boehringer Ingelheim GmbH, Daiichi Sankyo Company, and Aspen Pharmacare Holdings Limited, among others
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global thrombin inhibitor market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global thrombin inhibitor market

Detailed Segmentation:

By Type:
- Direct Thrombin Inhibitors
- Indirect Thrombin Inhibitors
By Application:
- Deep Vein Thrombosis (DVT)
- Pulmonary Embolism (PE)
- Atrial Fibrillation (AF)
- Others (Stroke Prevention, Acute Coronary Syndrome, etc.)
By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Company Profiles:
- Eisai Co., Ltd.
- Merck & Co., Inc.
- Novartis International AG
- GlaxoSmithKline plc
- AbbVie Inc.
- Portola Pharmaceuticals, Inc.
- CSL Behring
- Johnson & Johnson
- Sanofi S.A.
- Bayer AG
- Pfizer Inc.
- Bristol Myers Squibb
- Boehringer Ingelheim GmbH
- Daiichi Sankyo Company
- Aspen Pharmacare Holdings Limited

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Thrombin Inhibitor, By Type
- Market Thrombin Inhibitor, By Application
- Market Thrombin Inhibitor, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Impact Analysis
Key Highlights
Regulatory Scenario
Product launch/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario

4. Thrombin Inhibitor Market - Impact of Coronavirus (COVID-19) Pandemic

COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact

5. Thrombin Inhibitor Market, By Type, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2020 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Direct Thrombin Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
Indirect Thrombin Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)

6. Thrombin Inhibitor Market, By Application, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2020 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Deep Vein Thrombosis (DVT)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
Pulmonary Embolism (PE)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
Atrial Fibrillation (AF)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
Others (Stroke Prevention, Acute Coronary Syndrome, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)

7. Thrombin Inhibitor Market, By Region, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2020 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
  - U.S.
  - Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
  - U.K.
  - Germany
  - France
  - Italy
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
  - China
  - Japan
  - India
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
  - South Africa
  - North Africa
  - Central Africa

8. Competitive Landscape

Eisai Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Novartis International AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
GlaxoSmithKline plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
AbbVie Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Portola Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
CSL Behring
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Sanofi S.A.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Bayer AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Bristol Myers Squibb
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Boehringer Ingelheim GmbH
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Daiichi Sankyo Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Aspen Pharmacare Holdings Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Analyst Views